Catalent appoints Shannon Trilli to strengthen its corporate responsibility initiatives
Will coordinate and organize the company’s existing initiatives in sustainability and maximizing social impact, and its employee-driven community programs.
Catalent Pharma Solutions has appointed Ms. Shannon Trilli in the newly created role of Director of Corporate Responsibility.
In her post, Ms Trilli will be responsible for implementing Catalent’s global corporate responsibility strategy. She will strengthen Catalent’s efforts in this area, which will continue to be led by its Corporate Responsibility Council, composed of senior Catalent leaders from multiple functions. Ms Trilli will coordinate and organize Catalent’s existing initiatives in sustainability and maximizing social impact, and its employee-driven community programs. She will also lead Catalent’s activities in establishing additional programs, including the matching of gifts and strategic volunteer initiatives, and the expansion of the organization’s philanthropic and partnership portfolio.
Before joining Catalent, she served as the Director of Corporate Responsibility at S&P Global, a leading provider of transparent and independent ratings, benchmarks, analytics and data to capital and commodity markets worldwide.
Prior to S&P Global, Ms Trilli acted as the Director of Global Health for the United Methodist Committee on Relief (UMCOR). There, she designed, scaled and led UMCOR's Signature Health Program to provide funding and technical support to community based health organizations. She also led its $75 million "Imagine No Malaria" program in sub-Saharan Africa, with partners such as the U.N. Foundation and The Global Fund.
Ms Trilli has also served as a micro-enterprise development Peace Corps volunteer in Bolivia, and early in her career, was the manager of Global Employee Programs for the Contributions and Community Relations unit of The McGraw-Hill Companies.
"In addition to more deeply engaging our communities and demonstrating Catalent's commitment to and improving health and the environment, Shannon’s appointment and implementation of the corporate responsibility strategy will help us more meaningfully connect to employees, customers, and stakeholders,” commented Alessandro Maselli, Catalent’s Senior Vice President of Global Operations. He added, “In her new role, she will help us effectively communicate how Catalent’s capabilities and values result in positive social and business impacts, both in our local communities and across the globe."
Ms Trilli earned a bachelor's in government from the University of Texas in Austin, and a master's degree in public administration from New York University.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance